sharp acceler tavr growth tailwind
strengthen pt
ew saw signific acceler tavr growth last
compani credit posit low-risk data spur tavr adopt broadli full-
year guidanc rais upper end previou tavr
updat ncd pend low-risk approv eas comp model still look
conserv tavr prove naysay wrong mitral start
ramp come pt
tavr growth strong beat overal tavr growth improv
last us tavr growth improv high-teen low-doubl digit
strong result credit uptick tavr volum broadli across already-
approv risk strata follow earli march data though commentari
suggest low-risk contribut remain minim pend formal approv
share price describ stabl global on-going continu access
program also littl contribut improv growth low risk approv
still come updat ncd expect add center current
tavr market outlook remain good ew compani best-in-class valv
continu focu expand access market keep growth equal
guidanc rais though still conserv despit almost doubl growth
sequenti sever big driver yet hit low risk ncd tavr
guidanc rais upper end previou rang explain
guid ew note along posit tailwind tavr decis scuttl
centera focu tri true sapien platform pend competit
still consid model settl upper end though think
bia tavr number look posit mitral better
model recept pascal eu prove guidanc kept
though share take opportun monopoli eu
bia upsid
data right predict see improv analysi data
tavr purchas site one-third market prove predict
direct trend data may show us growth acceler
link updat recent june data link show versu
low doubl digit report strongli suggest ew would see uptick
growth sever surveys/model convers predict weaker singl
 entir valid model seem work
rais pt tavr provid durabl foundat growth ew
part increas awar treatment compani put tavr
compound-annual-growth-rate long tail tavr provid ampl time bridg mitral tricuspid
ew could see second act even bigger first remain rare
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
opportun growth outlook believ ew deserv trade
top peer group pt goe ep
pleas see import disclosur inform page report
edward tavr market leader develop
key driver growth valuat
us growth remain robust
progress mitral continu could substanti
pt earn in-lin
competit price
signific expans patient popul
market share
forecast new
technolog label expans
earlier commerci rapid market
develop mitral
upsid tavr market growth share assumpt
faster tmvr market develop assum dcf
would support upsid translat
pe ratio premium high-growth peer
slower adopt tavr
flatten penetr us and/or price
declin competit increas
inroad competitor tavr program lower ew
delays/setback mitral
conserv assumpt dcf model point
stock price translat pe ratio
discount high-growth peer
anticip strong adopt tavr ew
sapien valv next sever year base
posit clinic data technolog advanc
rate extent tavr adopt remain key
variabl though uptak market size thu far
exceed even bullish forecast
mitral could substanti expand address
market transcathet valv
low-risk fda clearanc tavr
clinic regulatori commerci develop
edward competitor tavr program
progress penetr global tavr market
progress mitral pipelin program
pleas see import disclosur inform page report
pleas see import disclosur inform page report
total growth sale gross ensestot oper oper oper expens inc incom incom tax ens incom growth dilut yr/yr sale tavr products/ growth ex fx ex fx return mitral yr/yr valv thvt yr/yr growth ex fx valv therapi yr/yr discontinu products/stock growth ex fx yr/yr discontinu growth ex fx yr/yr disc growth ex fx equiti research
edward lifesci provid product technolog treat advanc cardiovascular diseas offer product
transcathet treatment valvular heart diseas surgic valv devic critic care technolog
pt earn in-lin large-cap growth peer risk includ pipelin setback competit price
raj denhoy certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
anthoni petron cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
pleas see import disclosur inform page report
